查詢結果分析
相關文獻
- 治療膀胱過動症的新選擇--Tolterodine
- Tolterodine (Detrusitol[feb9])--治療膀胱過動症的新藥
- Effects of Tolterodine on Lower Urinary Tract Symptoms and Voiding Efficiency in Taiwanese Patients with an Overactive Bladder
- 膀胱過動症
- 膀胱過動症的治療
- 膀胱過動症治療用藥-Propiverine
- 膀胱過動症--定義、感行率、生理病理機轉和治療原則
- 物理治療於婦女尿失禁之應用
- 膀胱過動症(Overactive Bladder)藥物治療機轉
- 抗膽鹼藥物於膀胱過動症之治療
頁籤選單縮合
題名 | 膀胱過動症之藥物治療新進展=New Drug Therapy in Advance for Overactive Bladder |
---|---|
作者 | 陳佳南; 賴輝雄; 林慧娟; Chen, Chia-nan; Lai, Hui-hsiung; Lin, Hui-chuan; |
期刊 | 藥學雜誌 |
出版日期 | 20160600 |
卷期 | 32:2=127 2016.06[民105.06] |
頁次 | 頁45-50 |
分類號 | 418.22 |
語文 | chi |
關鍵詞 | 膀胱過動症; Overactive bladder; Antimuscarinics; β3-adrenoceptor agonists; Botulinum toxin; |
中文摘要 | 膀胱過動症臨床症狀以尿液急迫感來表現,通常伴隨有頻尿和夜尿症,也可能伴隨 急迫性尿失禁,但沒有明顯的病理疾病或是泌尿道感染。至今膀胱過動症治療藥物仍以 抗毒蕈鹼藥物為主軸,近期 AUA/SUFU 於2015年發表的治療指引中,增加了第二線療 法 β3-腎上腺受體作用劑和第三線的膀胱內注射肉毒桿菌毒素藥物。本文章即針對膀胱 過動症的治療藥物發展近況作全面性介紹並進行討論,以提供臨床藥物選擇參考,使病 人獲得最好的治療效果和最少的副作用產生。 |
英文摘要 | Overactive bladder (OAB) is the presence of urinary urgency, usually accompanied by frequency and nocturia, with or without urgency urinary incontinence, in the absence of a urinary tract infection or other obvious pathology. Antimuscarinics have been up to date, the mainstay of OAB treatment. Recently, AUA/SUFU guideline amendment published in 2015 introduced oral b3-adrenoceptor agonists and intravesical administration of botulinim toxin as second-line and third-line treatment respectively. This article focused on the development status and discussions of new drugs for OAB to provide physician choices of the appropriate selection agents. Further to establish treatment goals that maximize symptom control and patient quality of life while minimizing adverse events and patient burden. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。